A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Completed

Phase 3 Results

Summary of Purpose

The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 25 August 2010.

1 Nov 2004 24 Nov 2004 1 Jul 2007 1 Jul 2007 1 Aug 2010 19 Apr 2010
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Elliott M. Antman, M.D. Cardiovascular Division Brigham and Women’s Hospital TIMI Study Group 350 Longwood Ave., 1st Fl. Boston, MA 02115 Phone: 1-877-285-4559

    eantman@rics.bwh.harvard.edu